JUSTIN MAHR: Open Payments
NPI 1255981841 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$933 in 22 payments from 6 companies in 2025. Trend: 2023 $601 · 2024 $881 · 2025 $933
Food & beverage: $933
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 8 | $272 |
| Madrigal Pharmaceuticals | 5 | $270 |
| Ipsen Biopharmaceuticals, Inc | 3 | $168 |
| Intercept Pharmaceuticals, Inc. | 1 | $97 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
Products named: REZDIFFRA, Livdelzi, IQIRVO, OCALIVA, XIFAXAN, LIVTENCITY.
Industry payments across DE — which companies pay providers there.
